Immunogen Inc. (IMGN) Elahere Data 'Simply Mirvelous!' - BMO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Immunogen (IMGN) surges on 'home run' ovarian cancer treatment trial data
May 3, 2023 10:19 AM EDTImmunogen (NASDAQ: IMGN) shares more than doubled Wednesday after the company announced positive top-line data from its Phase 3 confirmatory MIRASOL trial.
The trial evaluated the safety and efficacy of Elahere compared to chemotherapy in patients with a type of ovarian cancer.
At the time of writing, ImmunoGen's stock price is currently up 134% at $12.20 per share.
The company said Elahere demonstrated a statistically significant and clinically meaningful... More
Immunogen Inc. (IMGN) PT Raised to $15 at Truist Securities on 'Home Run' Data
May 3, 2023 7:35 AM EDTTruist Securities analyst Asthika Goonewarden raised the price target on Immunogen Inc. (NASDAQ: IMGN) to $15.00 (from $11.00) while maintaining a Buy rating, calling today's data a "home run."
The analyst commented, "We view the topline data reported this morning as a home run. MIRASOL not... More
Immunogen (IMGN) Climbs 89% After Study Shows OS Benefit in Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer
May 3, 2023 7:09 AM EDTImmunogen (NASDAQ: IMGN) Climbs 89% After Study Shows OS Benefit in Phase 3 MIRASOL Trial in Patients with FR-Positive Platinum-Resistant Ovarian Cancer
Results Show Statistically Significant Improvements in PFS, ORR, and OS Compared to ChemotherapyFirst Medicine to Demonstrate an Overall Survival Advantage in... MoreImmunogen (IMGN) Reports ELAHERE Demonstrated Overall Survival Benefit in Phase 3 Trial
May 3, 2023 6:41 AM EDTImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced positive top-line data from the Phase 3 confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of ELAHERE® (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FR)-positive platinum-resistant ovarian cancer who have received one to three prior lines of therapy. Based on these data, the Company plans to submit a Marketing Authorization Application (MAA) in Europe and a supplemental Biologics License Application (sBLA) in the US for... More
